261 related articles for article (PubMed ID: 25917876)
1. Clinical Pharmacokinetic Studies of Enzalutamide.
Gibbons JA; Ouatas T; Krauwinkel W; Ohtsu Y; van der Walt JS; Beddo V; de Vries M; Mordenti J
Clin Pharmacokinet; 2015 Oct; 54(10):1043-55. PubMed ID: 25917876
[TBL] [Abstract][Full Text] [Related]
2. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.
van Nuland M; Bergman AM; Rosing H; de Vries N; Huitema ADR; Beijnen JH
Pharmacotherapy; 2019 Dec; 39(12):1137-1145. PubMed ID: 31596947
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.
Krauwinkel W; Noukens J; van Dijk J; Popa S; Ouatas T; de Vries M; Phung D; Gibbons J; Mordenti J; Mateva L
J Clin Pharm Ther; 2017 Jun; 42(3):268-275. PubMed ID: 28251667
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.
Joulia ML; Carton E; Jouinot A; Allard M; Huillard O; Khoudour N; Peyromaure M; Zerbib M; Schoemann AT; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Clin Genitourin Cancer; 2020 Apr; 18(2):155-160. PubMed ID: 31630979
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic Drug Interaction Studies with Enzalutamide.
Gibbons JA; de Vries M; Krauwinkel W; Ohtsu Y; Noukens J; van der Walt JS; Mol R; Mordenti J; Ouatas T
Clin Pharmacokinet; 2015 Oct; 54(10):1057-69. PubMed ID: 25929560
[TBL] [Abstract][Full Text] [Related]
6. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
Kim CS; Choi YD; Lee SE; Lee HM; Ueda T; Yonese J; Fukagai T; Chiong E; Lau W; Abhyankar S; Theeuwes A; Tombal B; Beer TM; Kimura G
Medicine (Baltimore); 2017 Jul; 96(27):e7223. PubMed ID: 28682871
[TBL] [Abstract][Full Text] [Related]
7. A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer.
Puszkiel A; Plé A; Huillard O; Noé G; Thibault C; Oudard S; Goldwasser F; Vidal M; Alexandre J; Blanchet B
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jul; 1058():102-107. PubMed ID: 28545929
[TBL] [Abstract][Full Text] [Related]
8. U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Ning YM; Brave M; Maher VE; Zhang L; Tang S; Sridhara R; Kim G; Ibrahim A; Pazdur R
Oncologist; 2015 Aug; 20(8):960-6. PubMed ID: 26070917
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide.
Benoist GE; Hendriks RJ; Mulders PF; Gerritsen WR; Somford DM; Schalken JA; van Oort IM; Burger DM; van Erp NP
Clin Pharmacokinet; 2016 Nov; 55(11):1369-1380. PubMed ID: 27106175
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety of Enzalutamide in Healthy Chinese Male Volunteers.
Liu YM; Wu P; Fukushi R; Yamada S; Chen Q
Clin Ther; 2019 Feb; 41(2):261-268. PubMed ID: 30642613
[TBL] [Abstract][Full Text] [Related]
11. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
[TBL] [Abstract][Full Text] [Related]
12. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.
Fizazi K; Scher HI; Miller K; Basch E; Sternberg CN; Cella D; Forer D; Hirmand M; de Bono JS
Lancet Oncol; 2014 Sep; 15(10):1147-56. PubMed ID: 25104109
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
[TBL] [Abstract][Full Text] [Related]
14. Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters.
Weiss J; Kocher J; Mueller C; Rosenzweig S; Theile D
Biopharm Drug Dispos; 2017 Dec; 38(9):517-525. PubMed ID: 28865089
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
Armstrong AJ; Halabi S; Healy P; Alumkal JJ; Winters C; Kephart J; Bitting RL; Hobbs C; Soleau CF; Beer TM; Slottke R; Mundy K; Yu EY; George DJ
Eur J Cancer; 2017 Aug; 81():228-236. PubMed ID: 28502694
[TBL] [Abstract][Full Text] [Related]
16. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
[TBL] [Abstract][Full Text] [Related]
17. Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.
Belderbos BPS; Bins S; van Leeuwen RWF; Oomen-de Hoop E; van der Meer N; de Bruijn P; Hamberg P; Overkleeft ENM; van der Deure WM; Lolkema MP; de Wit R; Mathijssen RHJ
Clin Cancer Res; 2018 Feb; 24(3):541-546. PubMed ID: 29150561
[No Abstract] [Full Text] [Related]
18. The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients.
Benoist GE; van Oort IM; Burger DM; Mehra N; van Erp NP
Cancer Chemother Pharmacol; 2020 Apr; 85(4):753-760. PubMed ID: 32076807
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.
Kim KP; Parise RA; Holleran JL; Lewis LD; Appleman L; van Erp N; Morris MJ; Beumer JH
J Pharm Biomed Anal; 2017 May; 138():197-205. PubMed ID: 28219796
[TBL] [Abstract][Full Text] [Related]
20. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]